Spyre Therapeutics
SYRE
85 hedge funds and large institutions have $189M invested in Spyre Therapeutics in 2021 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 26 increasing their positions, 22 reducing their positions, and 9 closing their positions.
100% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 9
18% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 22
10% more funds holding
Funds holding: 77 → 85 (+8)
6% more call options, than puts
Call options by funds: $263K | Put options by funds: $248K
0.07% less ownership
Funds ownership: 3.31% → 3.24% (-0.07%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
41% less capital invested
Capital invested by funds: $322M → $189M (-$133M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$8.19M |
| 2 |
LCM
Laurion Capital Management
New York
|
+$5.33M |
| 3 |
SCM
Suvretta Capital Management
New York
|
+$2.61M |
| 4 |
D.E. Shaw & Co
New York
|
+$1.26M |
| 5 |
CAM
ClariVest Asset Management
San Diego,
California
|
+$1.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$15.8M |
| 2 |
O
OrbiMed
New York
|
-$6.69M |
| 3 |
Millennium Management
New York
|
-$2.18M |
| 4 |
ACM
Altium Capital Management
New York
|
-$1.99M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$1.73M |
SYRE Hedge Fund Activity: Q4 2021 in Review
85 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Spyre Therapeutics (SYRE) for Q4 2021, worth a combined $189M — down 41% from $322M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new SYRE positions and 9 closed out — a net gain of 9 holders — while 26 added to existing stakes and 22 trimmed.
The largest buyer was Nantahala Capital Management, adding an estimated $8.19M. The largest seller was Adage Capital Partners, cutting an estimated $15.8M.
- 85 institutional investors held Spyre Therapeutics (SYRE) as of Q4 2021, up from 77 in Q3 2021.
- Funds reported $189M of Spyre Therapeutics stock for Q4 2021, down 41% quarter-over-quarter.
- 18 funds opened new Spyre Therapeutics positions in Q4 2021 and 9 closed out, a net change of +9 holders.
- The largest Spyre Therapeutics buyer in Q4 2021 was Nantahala Capital Management, an estimated $8.19M added.
- The largest Spyre Therapeutics seller in Q4 2021 was Adage Capital Partners, an estimated $15.8M sold.
Based on aggregated 13F filings for Q4 2021.